Thrombogenic role of cells undergoing apoptosis

British Journal of Haematology

Volumn 115, Issue 2, 2001, Pages 382-391

  Wang, Jun ^a   Weiss, Ivy ^a   Svoboda, Kristen ^a   Kwaan, Hau C ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Phosphatidylserine; Procoagulant; Thrombin generation; Tissue factor

Indexed keywords

CAMPTOTHECIN; FAS LIGAND; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; PHOSPHATIDYLSERINE; PROPIDIUM IODIDE; THROMBIN; THROMBOPLASTIN;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION FUNCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; THROMBIN TIME; THROMBOGENICITY; TUMOR CELL LINE;

ANNEXIN A5; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PHOSPHATIDYLSERINES; THROMBIN; THROMBOPLASTIN; TUMOR CELLS, CULTURED;

EID: 0035724408     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03095.x     Document Type: Article

References (42)

1. Oyxsterols induce membrane procoagulant activity in monocytic THP-1 cells
2. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: Induction of cooperativity by phosphatidylserine
3. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia
4. Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine
5. Apoptotic vascular endothelial cells become procoagulant
6. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: Implications for coagulation events and antigenic spread in systemic lupus erythematosus
7. Antigen and functional expression of tissue factor in endotoxin stimulated U937 cells: Regulation of activity by calcium ionophore A23187
8. Effects of raloxifene on postmenopausal women
9. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line
10. Abnormalities of blood coagulation tests in patients with cancer
11. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages
12. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by retinoic acid
13. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic cells
14. In vitro generation of procoagulant activity by leukemic promyelo-cytes in response to cytotoxic drugs
15. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
16. Thrombin generation by apoptotic vascular smooth muscle cells
17. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients
18. Cancer cell procoagulants and their implications
19. Apoptosis is associated with increased cell surface tissue factor procoagulant activity
20. Elevated TFPI in malignant disease: Relation to cancer type and hypercoagulation
21. Comparison of lipid binding and kinetic properties of normal, variant and gamma-carboxyglutamic acid modified human factor IX and factor IXa
22. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis
23. The thrombophilic state induced by therapeutic agents in the cancer patient
24. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer
25. The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor IXa
26. Surface-dependent hemostasis
27. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl
28. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells
29. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation
30. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer
31. Tissue factor as a tumor procoagulant
32. Hemostatic alterations in cancer patients
33. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathophysiologic and therapeutic features
34. Cancer and clotting - Trousseau's warning
35. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I or II inhibitors
36. Reassessing the hemostatic disorder associated with acute promyelocytic leukaemia
37. New insights into the pathogenesis of coagulation dysfunction in acute promelocytic leukaemia
38. Phlegmasia alba doleus
39. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumour cells and recognition by activated human blood monocytes
40. The role of phospholipid and factor VIIIa in the activation of bovine factor X
41. Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: Role for 43 000 Fas in VES-triggered apoptosis
42. Kinetics of factor IX activation via the extrinsic pathway